


WHAT IS CLAIMED IS:

- 1 1. A solid form of Compound I:



2
3 or a hydrate or solvate thereof.

- 1 2. The solid form of claim 1 characterized by an XRPD pattern comprising
2 one or more peaks at 6.9, 8.0, 8.2, 12.5, 12.7, 14.8, 15.0, 15.7, 16.8, 18.1, 18.8, 19.2, 20.6, 21.1,
3 21.8, 24.9, 27.1, or 27.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$
4 radiation.

- 1 3. The solid form of claim 2 characterized by an XRPD pattern comprising
2 two or more peaks at 6.9, 8.0, 8.2, 12.5, 12.7, 14.8, 15.0, 15.7, 16.8, 18.1, 18.8, 19.2, 20.6, 21.1,
3 21.8, 24.9, 27.1, or 27.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$
4 radiation.

- 1 4. The solid form of claim 3 characterized by an XRPD pattern comprising
2 three or more peaks at 6.9, 8.0, 8.2, 12.5, 12.7, 14.8, 15.0, 15.7, 16.8, 18.1, 18.8, 19.2, 20.6, 21.1,
3 21.8, 24.9, 27.1, or 27.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$
4 radiation.

- 1 5. The solid form of any of claims 1-4, characterized by an XRPD pattern
2 comprising peaks at 6.9, 8.2, and 15.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made
3 using $\text{CuK}\alpha 1$ radiation.

- 1 6. The solid form of claim 5, further comprising one or more peaks at 14.8,
2 15.0, 18.8, or 21.1 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$
3 radiation.

1 7. The solid form of claim **5**, further comprising two or more peaks at 14.8,
2 15.0, 18.8, or 21.1 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$
3 radiation.

1 8. The solid form of claim **5**, further comprising three or more peaks at 14.8,
2 15.0, 18.8, or 21.1 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$
3 radiation.

1 9. The solid form of any of claims **1-8**, characterized by an X-ray powder
2 diffraction (XRPD) pattern having peaks at 6.9, 8.2, 15.7, and 18.8 degrees 2θ (± 0.1 degrees
3 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$ radiation.

1 10. The solid form of any of claims **1-9**, characterized by an X-ray powder
2 diffraction (XRPD) pattern having peaks at 6.9, 8.2, 12.5, 14.8, 15.7, and 18.8 degrees 2θ (± 0.1
3 degrees 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$ radiation.

1 11. The solid form of any of claims **1-10**, characterized by an X-ray powder
2 diffraction (XRPD) pattern having peaks at 6.9, 8.2, 12.5, 14.8, 15.7, 18.8, and 21.1 degrees 2θ
3 (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$ radiation.

1 12. The solid form of any of claims **1-11**, characterized by an X-ray powder
2 diffraction (XRPD) pattern having peaks at 6.9, 8.2, 12.5, 14.8, 15.7, 18.8, 20.6, and 21.1
3 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$ radiation.

1 13. The solid form of any of claims **1-12**, characterized by an X-ray powder
2 diffraction (XRPD) pattern having peaks at 6.9, 8.2, 12.5, 14.8, 15.7, 18.8, 20.6, 21.1, and 27.7
3 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}_{\alpha 1}$ radiation.

1 14. The solid form of any one of claims **1-13**, characterized by an X-ray
2 powder diffraction pattern (XRPD) having peaks at 6.9, 8.0, 8.2, 12.5, 12.7, 14.8, 15.0, 15.7,
3 16.8, 18.1, 18.8, 19.2, 20.6, 21.1, 21.8, 24.9, 27.1, or 27.7 degrees 2θ (± 0.1 degrees 2θ), wherein
4 the XRPD is made using $\text{CuK}_{\alpha 1}$ radiation.

1 **15.** The solid form of any one of claims **1-14**, characterized by an X-ray
2 powder diffraction pattern (XRPD) substantially in accordance with that of Figure 1.

1 **16.** The solid form of any one of claims **1-15**, characterized by a unit cell as
2 determined by single crystal X-ray crystallography of the following dimensions: $a = 15.1880$ (7)
3 Å; $b = 20.9125$ (11) Å; $c = 7.5242$ (4) Å; $\alpha = 90^\circ$; $\beta = 90.7720$ (10) °; and $\gamma = 90^\circ$.

1 **17.** The solid form of any one of claims **1-16**, characterized by a differential
2 scanning calorimetry (DSC) pattern having an endotherm at about 193 °C.

1 **18.** The solid form of any one of claims **1-17**, characterized by a differential
2 scanning calorimetry (DSC) pattern substantially in accordance with that of Figure 2.

1 **19.** A pharmaceutical composition comprising a solid form of any one of
2 claims **1-18** and a pharmaceutically acceptable excipient.

1 **20.** A method of treating a disease, disorder, or condition, mediated at least in
2 part by the adenosine A_{2A} receptor ($A_{2A}R$) or the adenosine A_{2B} receptor ($A_{2B}R$), said method
3 comprising administering a therapeutically effective amount of a solid form of any one of claims
4 **1-18** to a subject in need thereof.

1 **21.** The method of claim **20**, wherein said disease, disorder, or condition is
2 mediated at least in part by $A_{2A}R$.

1 **22.** The method of claim **20**, wherein said disease, disorder, or condition is
2 mediated at least in part by $A_{2B}R$.

3 **23.** The method of claim **20**, wherein said disease, disorder, or condition is
4 mediated at least in part by both the $A_{2A}R$ and $A_{2B}R$ receptors.

1 **24.** The method of claim **21**, wherein said solid form is administered in an
2 amount effective to reverse or stop the progression of $A_{2A}R$ -mediated immunosuppression.

1 **25.** The method of any one of claims **20-24**, wherein said disease, disorder, or
2 condition is cancer.

1 **26.** The method of claim **25**, wherein said cancer is a cancer of the prostate,
2 colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head,
3 neck, skin (including melanoma and basal carcinoma), mesothelial lining, white blood cell
4 (including lymphoma and leukemia), esophagus, breast, muscle, connective tissue, lung
5 (including small-cell lung carcinoma and non-small-cell lung carcinoma), adrenal gland, thyroid,
6 kidney, or bone; or is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma,
7 sarcoma (including Kaposi's sarcoma), choriocarcinoma, cutaneous basocellular carcinoma, or
8 testicular seminoma.

1 **27.** The method of claim **25**, wherein said cancer is selected from the group
2 consisting of melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung
3 cancer, leukemia, a brain tumor, lymphoma, ovarian cancer, and Kaposi's sarcoma.

1 **28.** The method of claim **20-24**, wherein said disease, disorder, or condition is
2 an immune-related disease, disorder or condition.

1 **29.** The method of claim **28**, wherein said immune-related disease, disorder,
2 or condition is selected from the group consisting of selected from the group consisting of
3 rheumatoid arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies,
4 fibrosis, anemia fibromyalgia, Alzheimer's disease, congestive heart failure, stroke, aortic valve
5 stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, infections, Crohn's disease,
6 ulcerative colitis, allergic contact dermatitis and other eczemas, systemic sclerosis and multiple
7 sclerosis.

1 **30.** A pharmaceutical composition comprising a solid form of any one of
2 claims **1-18**, and at least one additional therapeutic agent.

1 **31.** The pharmaceutical composition of claim **30**, wherein the at least one
2 additional therapeutic agent is a chemotherapeutic agent, an immune- and/or inflammation-
3 modulating agent, an anti-hypercholesterolemia agent, an anti-infective agent, or radiation.

1 **32.** The pharmaceutical composition of claim **30**, wherein the at least one
2 additional therapeutic agent is an immune checkpoint inhibitor.

1 **33.** The pharmaceutical composition of claim **32**, wherein said immune
2 checkpoint inhibitor blocks the activity of at least one of PD1, PDL1, or CTLA4.

1 **34.** A method of treating cancer in a subject, said method comprising
2 administering to said subject an effective amount of a solid form of any one of claims **1-18** and at
3 least one additional therapeutic agent.

1 **35.** The method of claim **34**, wherein the at least one additional therapeutic
2 agent is an immune checkpoint inhibitor.


1 **36.** The method of claim **35**, wherein said immune checkpoint inhibitor blocks
2 the activity of at least one of PD1, PDL1, or CTLA4.

1 **37.** The method of any one of claims **34-36**, further comprising a
2 chemotherapeutic agent.

1 **38.** The method of any one of claims **34-37**, wherein said solid form, said
2 immune checkpoint inhibitor, and/or said chemotherapeutic agent are administered in
3 combination.

1 **39.** The method of any one of claims **34-38**, wherein the treatment periods for
2 the administration of said solid form, said immune checkpoint inhibitor, and said
3 chemotherapeutic agent overlap.

1 **40.** A method of preparing a solid form of the compound of any one of claims
2 **1 to 18**, comprising:
3 forming a mixture comprising Compound I:



5 and a solvent comprising a C₃-C₅ ketone, dichloromethane, or toluene, under
6 conditions suitable to prepare the solid form of Compound I.

1 **41.** The method of claim **40**, wherein the solvent comprises acetone or 2-
2 butanone.

1 **42.** The method of claim **40** or **41**, further comprising heating the solvent.

1 **43.** The method of claim **42**, further comprising adding an anti-solvent after
2 the heating.


1 **44.** The method of claim **43**, wherein the anti-solvent comprises water,
2 pentane, heptane, or methyl tert-butyl ether.

1 **45.** The method of claim **40**, comprising heating Compound I in a solvent
2 comprising acetone to dissolve Compound I, and then adding an anti-solvent comprising water.

1

WHAT IS CLAIMED IS:

1. A crystalline form of Compound I:



wherein the crystalline form is characterized by an XRPD pattern comprising one or more peaks at 6.9, 8.0, 8.2, 12.5, 12.7, 14.8, 15.0, 15.7, 16.8, 18.1, 18.8, 19.2, 20.6, 21.1, 21.8, 24.9, 27.1, or 27.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$ radiation.

2. The crystalline form according to claim 1, characterized by an XRPD pattern comprising peaks at 6.9, 8.2, and 15.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$ radiation.

3. The crystalline form according to claim 1 or 2, further comprising one or more peaks at 14.8, 15.0, 18.8, or 21.1 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$ radiation.

4. The crystalline form according to any one of claims 1-3, characterized by an X-ray powder diffraction pattern (XRPD) having peaks at 6.9, 8.0, 8.2, 12.5, 12.7, 14.8, 15.0, 15.7, 16.8, 18.1, 18.8, 19.2, 20.6, 21.1, 21.8, 24.9, 27.1, or 27.7 degrees 2θ (± 0.1 degrees 2θ), wherein the XRPD is made using $\text{CuK}\alpha 1$ radiation.

5. The crystalline form according to any one of claim 1-4, wherein the crystalline form is substantially free of other crystalline forms of Compound 1.

6. The crystalline form according to any one of claims 1-5, characterized by a unit cell as determined by single crystal X-ray diffraction of the following dimensions: $a = 15.1880(7) \text{ \AA}$; $b = 20.9125(11) \text{ \AA}$; $c = 7.5242(4) \text{ \AA}$; $\alpha = 90^\circ$; $\beta = 90.7720(10)^\circ$; and $\gamma = 90^\circ$.

7. The crystalline form of any one of claims 1-6, characterized by a differential scanning calorimetry (DSC) pattern having an endotherm at about 193 °C.

8. A pharmaceutical composition comprising a crystalline form according to any one of claims 1-7 and a pharmaceutically acceptable excipient.

9. Use of a therapeutically effective amount of a crystalline form according to any one of claims 1-7, or a pharmaceutical composition of claim 8, in the preparation of a medicament for treating a disease, disorder, or condition, mediated at least in part by the adenosine A_{2A} receptor (A_{2A}R) or the adenosine A_{2B} receptor (A_{2B}R) or both the A_{2A}R and A_{2B}R receptors.

10. The use according to claim 9, wherein said disease, disorder, or condition is cancer.

11. The use according to claim 10, wherein said cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone; or is glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, or testicular seminoma.

12. The use according to claim 11, wherein said cancer is non-small-cell lung carcinoma.

13. The use according to claim 11, wherein said cancer is prostate cancer.

14. The use according to claim 11, wherein said cancer is colon or rectal cancer.

15. The use according to claim 11, wherein said cancer is pancreatic cancer.

16. The use according to any one of claims 9-15, wherein the medicament is to be administered with at least one additional therapeutic agent.

17. The use according to claim 16, wherein the at least one additional therapeutic agent is an immune checkpoint inhibitor.

18. The use according to claim 17, wherein said immune checkpoint inhibitor blocks the activity of at least one of PD-1, PD-L1, TIGIT or CTLA-4.